This hypothesis was clinically tested in a Phase I/II trial (NCT03041701) [303] evaluating ganitumab (AMG479), an IGF-1R antibody, in combination with dasatinib in patients with relapsed or refractory ERMS and ARMS. This evidence concerns the gene IGF1R and alveolar rhabdomyosarcoma.